IBA Radcal Launches Accu-Gold Mobile: Bringing True Mobility to Diagnostic X-Ray QA

by | Dec 9, 2025 | News

IBA Radcal, a leader in diagnostic X-ray quality assurance solutions, has introduced its latest innovation: the Accu-Gold Mobile — a mobile platform designed to make X-ray Beam QA faster, simpler, and more flexible than ever before.

Building on the accuracy and reliability of the renowned Accu-Gold platform, the new MobileApp allows medical physicists, service engineers, and technicians to perform their QA workflows directly from a smartphone or tablet. Whether for radiography, fluoroscopy, mammography, or dental imaging, the app delivers instant access to real-time measurement data — without the need for a laptop or external PC.

“The Accu-Gold MobileApp brings a new level of freedom and efficiency to diagnostic QA,” says Daniel Boedeker, Director Product Lifecycle Management – Medical Imaging at IBA Dosimetry. “It combines the precision and trust of our Accu-Gold systems with the mobility today’s users expect in their daily work. You can perform measurements, review results, and store everything — all in the palm of your hand.”

The MobileApp connects seamlessly to Accu-Gold+ meters via WiFi, providing live readings of key parameters such as kV, dose, dose rate, exposure time, and HVL. Its intuitive interface, optimized for touch operation, features customizable displays and automatic data logging.

Beyond convenience, IBA Radcal focused on data integrity and workflow integration. Measurement data can be securely stored, exported, or shared for reporting and documentation — supporting both local and cloud-based QA processes.

“We developed the Accu-Gold Mobile to empower users to work wherever the measurement takes them — from clinical environments to field service,” Boedeker adds. “It’s a natural evolution of the Accu-Gold ecosystem, reflecting our ongoing commitment to innovation and user-centric design.”

The Accu-Gold Mobile is available for iOS and Android devices. Learn more on the product page here.

With this release, IBA Radcal reaffirms its mission: delivering precision where it counts — and mobility where it matters.

IBA integrates Artificial Intelligence Quality Assurance into dosimetry solutions through the acquisition of PhantomX GmbH

by | Nov 4, 2025 | News

Dosimetry portfolio strengthened with Medical Imaging QA and AI validation

Louvain-la-Neuve, Belgium, 03 November 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a world-leading provider of quality assurance (QA) solutions, today announces the acquisition of PhantomX GmbH, expanding IBA’s portfolio in healthcare diagnostics and therapeutic systems enabling artificial intelligence (AI) quality assurance.

Founded in 2018 by Dr. Paul Jahnke and Dr. Felix Schwarz, with support from Charité University Hospital in Berlin, PhantomX is a recognized leader in the development of realistic anthropomorphic phantoms. The company’s proprietary advanced quality assurance technologies are used globally for validating diagnostic and therapeutic imaging systems, as well as medical education and training. PhantomX is at the forefront of quality assurance for AI applications in medical imaging and provides tools for AI-enhanced clinical solutions.

“PhantomX’s expertise in AI validation perfectly complements IBA’s portfolio of Clinical Workflow Solutions in Radiation Therapy and Medical Imaging,” said Jean-Marc Bothy, President of IBA Dosimetry. “Together, we will accelerate innovation in our Medical Imaging Business Line with simulation and AI-driven technologies, delivering greater value to clinicians and patients worldwide.”

Dr. Paul Jahnke, one of the Founders of PhantomX, added: “This merger empowers us to bring our technology to new markets and contribute to the future of intelligent, safe, and effective medical solutions.”

***ENDS***

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as the most advanced form of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com.

For further information, please contact:

IBA Investor Relations
Thomas Pevenage
+32 10 475 890
investorrelations@iba-group.com

IBA Corporate Communication
Olivier Lechien
+32 10 475 890
communication@iba-group.com

Introducing T3, X-ray QA Meter

by | May 29, 2024 | News

We are very Proud to announce the release of our Brand New T3 series X-ray QA meters. At T3’s core is its unique ability to use profiles. Machine Specific Profiles are used to define the measurement process. They spell out trigger parameters, filtration requirements, the breakdown of the measurement (such as having a scout pulse) and the end of the pulse without user intervention. Special calibrations are built into the profiles eliminating the need to install calibration files. Profile selection allows you to specify different techniques for special measurements.  Profiles save time by eliminating manual user settings and often only one exposure is needed. For example, when using the Mammo Combo Mode Profile, with a Single exposure kV, Time, dose, and dose rate are captured for each region. T3’s CBCT Profile allows for the capture of DAP, kV and Dose with one exposure.  Frequently used Profiles can be saved as favorites.­­

  • T3 Series – A stand-alone meter with customizable display for quick, easy and reliable measurements. Ready to use in a flash.
  • T3 Professional Series – a meter with display and USB or Wi-Fi capability for extended use with your laptop or tablet computer. Using the Accu-Gold Windows application users are able to access a rich set of advanced capabilities such as automated Excel-based reporting and waveform analysis.

Visit T3 product pages for more details or please contact Sales@Radcal.com, 626-357-7921 ext 111.

Exciting News: IBA Successfully Acquires Radcal

by | Feb 9, 2024 | News

Today we are excited to announce the acquisition of Radcal by IBA. We look forward to a positive future that strengthens both companies market positions and expands resources for all.

Please join us in welcoming the IBA Team. We look forward to our continuing business and thank you for being a valued partner!

Highly complementary acquisition continues IBA’s expansion strategy to lead the Radiotherapy, Medical Imaging Dosimetry and Quality Assurance markets globally

Louvain-la-Neuve, Belgium, February 9, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a world-leading provider of dosimetry and quality assurance (QA) solutions, announced today it has signed an agreement to acquire all the assets of Radcal, a leader in diagnostic X-ray measurement based in California, USA. Through this acquisition, IBA will further strengthen its Medical Imaging Quality Assurance offering and its presence in the US market. Closing is expected on February 29, 2024. The acquisition is expected to be revenue accretive and EBIT positive from 2024.

Radcal is a pioneer in the X-ray imaging market, having introduced the first instrument providing comprehensive measures of X-ray dose with the ability to interchange sensors without loss in accuracy, almost 50 years ago. Today, Radcal’s systems remain a market leader, generating revenues of approximately USD 6 million in 2023 and employing 35 people.

The combination of Radcal into IBA’s business will support its continued growth in the dosimetry and quality assurance market, giving it an even greater foothold in the important US market and expanding its product offering beyond OEM and into the clinical setting. Further details of the acquisition were not disclosed.

Olivier Legrain, Chief Executive Officer at IBA, said: “This acquisition strengthens our position as a global leader in Medical Imaging Dosimetry and Quality Assurance, complementing our leading position in the radiotherapy market and diversifying our revenue sources. We see tremendous potential for the combined business both in the US and the international market and look forward to working closely with the Radcal team to continue the strong growth of its leading offering.”

Jean-Marc Bothy, President of IBA Dosimetry, added: “We are delighted to welcome the talented and dedicated Radcal team to IBA group. We are committed to providing the very best in medical imaging and radiotherapy quality assurance to our customers globally, contributing to our ultimate goal to treat more patients safely. Radcal’s growing product offering will enable us to reach new customers in the US and expand our presence in the Medical Imaging Quality Assurance market internationally.”

***ENDS**

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

 

 

NEW AND DEVELOPED FOR YOU!

by | Jun 17, 2020 | News

Radcal is excited to introduce our new 10X6-60DAP chamber for measuring DAP and DAP Rate on CBCT systems. This time saving chamber can be combined with any of our Accu-Gold+ or Touch System platforms and is an easy addition to our already comprehensive array of measurement capabilities.

The Chamber can display data in Gy-m2 and Gy-cm2.

If you have a Radcal meter or need a new meter with DAP measurement capability designed to measure on challenging CBCT systems please contact Sales@Radcal.com, 626-357-7921 ext 111.

Skip to content